Eevia revises date for release of Interim report Q3-2024
Eevia Health Plc ("Eevia" or "The Company") will publish its Interim report for the third quarter on November 29 due to the onboarding of a new Board and one large unforeseen urgent project that appeared a week ago.
Eevia shareholders elected a new Board on November 4. The Board has met once for a constitutional meeting and will meet again on November 20. However, as the board members, including the Chairman, are still being inducted into the Company, the Company wants to give the Board more time to review the status and the Interim Report.
In addition, the Company has been approached for a large, urgent project that will take up a significant part of the upcoming Board meeting. As such, this alone merits a later release of the third quarter report.
Eevia has therefore decided to postpone the Interim Report for Q3-24 to November 29, 2024.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: [email protected] or [email protected]
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as Bilberry, lingonberry, Chaga mushroom, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.
Om Eevia Health
Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.
